Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nedaplatin concurrent chemoradiotherapy for recurrent or locally advanced head and neck squamous cell carcinoma
ChiCTR2000034141Phase 4Recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Jun 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemcitabine and nedaplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Tianjin People's Hospital. Primary endpoints: objective response rate, disease control rate and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
gemcitabinenedaplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2000034141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034141.